HC Wainwright & Co. Upgrades AcelRx Pharmaceuticals to Buy, Announces $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has upgraded AcelRx Pharmaceuticals from Neutral to Buy and set a price target of $8.
August 18, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AcelRx Pharmaceuticals has been upgraded from Neutral to Buy by HC Wainwright & Co. with a new price target of $8.
The upgrade from Neutral to Buy indicates a positive outlook for AcelRx Pharmaceuticals. The new price target of $8 suggests that the analyst believes there is significant upside potential for the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100